SS-31 | TongPeptides | 99% Purity |10mg 50mg

SS‑31, also known as Elamipretide, MTP‑131 or Bendavia, is a synthetic mitochondria‑targeted tetrapeptide belonging to the Szeto‑Schiller peptide family. It efficiently crosses cell membranes and selectively accumulates within the inner mitochondrial membrane by binding to cardiolipin, a unique phospholipid abundant in mitochondria. SS‑31 stabilizes mitochondrial cristae structure, improves electron‑transport‑chain efficiency, enhances ATP generation, and scavenges mitochondrial reactive oxygen species (ROS). It alleviates oxidative‑stress‑mediated cell damage and inhibits excessive apoptosis signalingPMC. It is widely used in laboratory research covering mitochondrial bioenergetics, anti‑oxidation, cardiovascular protection, neurodegeneration and metabolic‑related mechanism studies. Our SS‑31 is supplied as high‑purity white lyophilized powder in sterile glass vials. For laboratory research use only, not approved for human clinical administration.

Retatrutide, development code LY3437943, is an innovative, lipid-conjugated long-acting triple G-protein coupled receptor agonist synthetic peptide independently developed by Eli Lilly, representing the next-generation landmark compound in incretin metabolic research. Unlike single-target GLP‑1 agonists (such as semaglutide) or dual GLP‑1/GIP agonists (such as tirzepatide), this single intact peptide molecule can simultaneously bind to and fully activate three core metabolic receptors: GLP‑1 receptor, GIP receptor and glucagon receptor, generating synergistic multi-pathway regulatory effects that dual-target peptides cannot achieve.
Structurally, Retatrutide is modified with specific unnatural amino acid substitutions and fatty acid side chain conjugation on a GIP peptide backbone. This special structural design greatly improves protease resistance and extends its blood circulation half-life to roughly 6 days, supporting once-weekly administration in clinical trial protocols and delivering stable, sustained biological activity without sharp hormonal fluctuations throughout the cycle.
Its comprehensive biological mechanisms work through three coordinated pathways. First, activated GLP‑1 and GIP receptors jointly act on the central hypothalamus and gastrointestinal tract: they significantly suppress excessive appetite, delay gastric emptying, enhance satiety signals, and drastically reduce spontaneous calorie intake from daily meals. Second, glucagon receptor activation triggers unique thermogenic effects, boosting whole-body basal energy expenditure, accelerating white adipose tissue lipolysis, inhibiting de novo fat synthesis in the liver and subcutaneous fat, and delivering far more prominent body fat reduction compared to dual agonists. Third, the triple receptor signaling cascade optimizes pancreatic islet function: it stimulates glucose-dependent insulin secretion, suppresses abnormal elevated glucagon secretion under hyperglycemic conditions, effectively stabilizes fasting and postprandial blood glucose, lowers HbA1c levels, and comprehensively repairs disrupted systemic metabolic homeostasisPMC.
A large number of Phase 2 and pivotal Phase 3 clinical trial data (the TRIUMPH and TRANSCEND-T2D research programs covering more than 5,800 global participants) have verified its powerful metabolic benefits. At the maximum 12mg weekly dosage, the average total body weight loss reached 28.3% after 80 weeks of continuous intervention; in type 2 diabetic subjects, up to 68% of participants achieved standard HbA1c ≤6.5%, with obvious improvements in triglycerides, blood pressure, liver fat infiltration and other cardiometabolic indicators. Therefore, Retatrutide is widely adopted in preclinical and clinical laboratory research targeting multiple populations: overweight adults, clinically obese individuals, obese patients complicated with type 2 diabetes mellitus, non-alcoholic fatty liver disease, and related metabolic comorbidities including hyperlipidemia and sleep apnea associated with obesity.
Our supplied Retatrutide is high-purity white lyophilized peptide powder sealed in sterile independent glass vials, with HPLC verified purity above 99%. Every production batch undergoes full-spectrum testing including high-performance liquid chromatography, mass spectrometry and impurity analysis, with complete test certificates provided for all orders to guarantee stable, consistent experimental performance for lab projects.
As of 2026, Retatrutide is still undergoing global Phase 3 registrational clinical trials and has not obtained official marketing approval from regulatory authorities such as the FDA or EMA. All Retatrutide products we supply are strictly limited to laboratory scientific research applications only, and are not authorized for human clinical injection, diagnosis, treatment or any off-label medical use.